Rally Foundation teams up with Oncoheroes against childhood cancer
Oncoheroes Biosciences, currently building a multi-asset portfolio of pediatric oncology drugs, announces the investment of Rally Foundation for Childhood Cancer Research. The startup –co-founded in 2017 in Boston by the Catalan entrepreneur Ricardo Garcia and the Italian scientist Cesare Spadoni, two parents touched by childhood cancer– has the European headquarters at the Barcelona Science Park. This is the first time that this North American non-profit organization is investing in a biotech company.
We are honored that for the first time, Rally Foundation have decided to go beyond funding academic research by investing in Oncoheroes. We believe focused disease foundations and patients’ associations play an essential role during the development of new drugs for rare diseases. Thank you Rally for joining the effort,” says Ricardo Garcia, CEO of Oncoheroes Biosciences.
We are thrilled to team up with Oncoheroes and support the effort of bringing new life-saving therapies for children and adolescents with cancer,” says Dean Crowe, co-founder and CEO of Rally Foundation.
Childhood cancer is considered a rare disease affecting 300,000 new families every year worldwide, 90,000 of them unfortunately will lose their loved one. Moreover, more than 95% of childhood cancer survivors will have health-related issues because of the cancer treatments administered, the vast majority designed and developed for adult indications. Despite this, only five pediatric cancer drugs have been approved in the last 40 years versus more than 200 for adults, pointing to a large unmet medical need.
» More information: Oncoheroes website [+]